Our findings provide initial evidence that p16 <sup>Ink4a</sup> -mediated cellular senescence is a primary driver of OSA-induced cardiovascular morbidity and that targeting the senescent endothelium can revert vascular dysfunction, thereby establishing a novel mechanistic framework for cellular senescence as a therapeutic target in OSA. This evidence concerns the gene CDKN2A and obstructive sleep apnea syndrome.